In this episode, TRC Healthcare editor, Rachel Cole, PharmD, unpacks the updated recommendations for H. pylori management, spotlighting why bismuth quadruple therapy is now front and center and how to navigate antibiotic resistance and patient-specific factors. You’ll come away with actionable pearls on regimen selection, adherence strategies, and which drug interactions to watch for.

This is an excerpt from our February 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:

• Article: Stay Current on H. pylori Treatment Guidance
• Chart: Helicobacter pylori: From Diagnosis to Eradication
• Graphic: Helicobacter pylori Treatment Summary

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools.

Use code cc1025 at checkout for 10% off a new subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

****

📝 We’d love to hear from you!

Take our quick listener survey—it only takes a minute and helps us make the show even better. Plus, you’ll be entered to win a $25 gift card!

📣 Share your thoughts here: https://forms.office.com/r/H2nLqzBwQc📣

****

Send us a text

If you’re not yet a subscriber, find out more about our product offerings at trchealthcare.com.

Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, digs into Suzetrigine—brand name Journavx—the first non-opioid analgesic approved in over two decades.

You’ll hear how it works, how it compares to hydrocodone/acetaminophen, and why it might be a game-changer for patients at risk of opioid misuse. We’ll also unpack limitations in the clinical trials, cost concerns, dosing nuances, and key drug interactions to watch for. Plus, we’ll share tips for counseling patients and navigating formulary decisions, especially if your site participates in the manufacturer’s pilot program.

Don’t miss our quick skim graphic and comparison resource to help you make informed decisions.

This is an excerpt from our April 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:

• Article: Explain How Suzetrigine Stacks Up for Acute Pain
• Graphic: New Drug: Suzetrigine (Journavx)
• Resource: Analgesics for Acute Pain in Adults

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools.

Use code cc1025 at checkout for 10% off a new subscription.

🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.

****

📝 We’d love to hear from you!

Take our quick listener survey—it only takes a minute and helps us make the show even better. Plus, you’ll be entered to win a $25 gift card!

📣 Share your thoughts here: https://forms.office.com/r/H2nLqzBwQc📣

****

Send us a text

If you’re not yet a subscriber, find out more about our product offerings at trchealthcare.com.

Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, discusses recently approved drug formulations that bring fresh options—and new challenges—to the pharmacy counter.

From Arbli, the first ready-to-use losartan suspension, to Emrosi, a low-dose minocycline for rosacea, and Opipza, an oral film version of aripiprazole, we’ll walk through what makes each product unique and what pharmacy teams should watch for. We also cover HemiClor, a 12.5 mg chlorthalidone tablet that may help patients avoid splitting unscored tabs, Neffy, a needle-free epinephrine nasal spray now available in a pediatric strength, and wrap up with biosimilar updates on Merilog and Omlyclo.

This is an excerpt from our June 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:

• Article: Watch for New Twists to Older Medications
• Chart: Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
• Chart: Treatments for Rosacea
• Chart: Comparison of Commonly Used Diuretics
• Chart: Comparison of Atypical Antipsychotics
• Chart: Emergency Epinephrine Devices
• Chart: Facts About Biosimilars

Use code cc1025 at checkout for 10% off a new subscription.

Send us a text

****

Join the National Community Pharmacists Associations’ Annual Convention (NCPA) in New Orleans October 18-21st: https://bit.ly/ncpameeting25

****

If you’re not yet a subscriber, find out more about our product offerings at trchealthcare.com.

Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.